Navigation Links
Positive results from Visudyne(R) combination therapy study reported at Annual Macula Society Conference
Date:3/28/2008

VANCOUVER, March 28 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced today that results from an investigator-sponsored Phase II study, in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD), showed that a combination therapy of verteporfin (Visudyne(R)) followed by bevacizumab (Avastin(R)) reduced, by half, the number of treatments required during the first six months to gain similar visual acuity compared to Avastin monotherapy. In addition, 30% of the patients treated using the combination therapy required only a single combination treatment compared to Avastin monotherapy, with which all patients required additional treatments.

Visudyne therapy is approved for the treatment of age-related macular degeneration (AMD) in patients with predominantly classic subfoveal choroidal neovascularization. QLT Inc. is the manufacturer of Visudyne.

Dr. Michael Potter, the investigator-sponsor of the verteporfin and bevacizumab (VIA) clinical trial, which was supported by QLT, presented results today at the 31st Annual Macula Society Meeting that is being held this week in Florida. The objective of the VIA study was to determine whether Visudyne, at low or very low fluence rates, in combination with Avastin, reduces the average number of treatments required, compared to Avastin alone.

"We are very pleased with the clinical outcomes of this study. Our goal was to see if it is possible to minimize the number of treatments while maintaining or improving visual acuity in patients with CNV secondary to AMD. At six months, virtually all the patients treated with the Visudyne combination therapy gained visual acuity with half the number of treatments required with Avastin monotherapy. These results are encouraging, and more research continues to be done to evaluate the benefits of combination therapy in terms of helping patients improve their vision and also reducing the cost of t
'/>"/>

SOURCE QLT Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Cystic Fibrosis Foundation announces positive early results for phase 2 clinical trial of VX-770
2. MRIs high false positive rate has little impact on womens choice of preventive mastectomy
3. AcroMetrix Announces Launch of First Liquid MRSA Positive Control
4. Make Your Mammogram a Positive Experience: Author Offers Guidelines and Tips to Change Womens Negative Attitudes Toward Mammograms
5. QLT announces positive FDA action on Aczone(TM)
6. Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor
7. Echo Therapeutics Announces Positive Results from Symphony(TM) Transdermal Continuous Glucose Monitoring System Study at Tufts Medical Center
8. Ibuprofen destroys aspirins positive effect on stroke risk
9. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
10. Positive results from phase 1 clinical trials of cuprindro
11. Single reader with CAD more efficient, yields fewer false positives, and possibly more sensitive
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... According to a new market research report ... (processor, GPU, DSP, connectivity), Technology Node (45nm-5nm), Application ... Forecast and Analysis to 2014-2020", published by MarketsandMarkets, ... is expected to reach $61.70 Billion by 2020, ... to 2020. , Browse 71 market data Tables ...
(Date:7/13/2014)... 13, 2014 A Massachusetts couple who ... cancer risks associated with power morcellators ( http://www.gynecaremorcellatorlawsuit.com/ ) ... to federal regulators, as they presented poignant testimony on ... Drug Administration (FDA) advisory panel meeting convened to address ... the Rochester Democrat and Chronicle, Dr. Hooman Noorchashm and ...
(Date:7/13/2014)... 2014 The Pearland, Texas location of The ... from four months to 12 years of age that offers ... birthday parties and Summer Camps, is now under new ownership. ... Pearland after spending over six years at The Little ... Director. , Berry has over ten years of experience ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 The federal ... ) filed against Johnson & Johnson’s Ethicon, ... trial, which is expected to get underway next month. ... the U.S. District Court, Southern District of West Virginia ... held on August 7, 2014 at 3:00 p.m. July ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Max ... Famer, Chris Mullin, will be the featured guest at ... 26th in Puerto Rico. Attendees will learn about ... participate in two exhibition basketball games and perform in ... supplier of health- and energy-boosting supplements , has ...
Breaking Medicine News(10 mins):Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 2Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 3Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 4Health News:The Little Gym of Pearland, TX Now Under New Ownership and Management 2Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 2Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 3Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 4Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 3Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 4
... , , , ... http://www.avacor.com ) has acquired the assets ... name; Avacor,s FDA approved Physicians, Topical Formulation(R); the All-Natural Nutricap and ... Application) which allows the company to market and sell the FDA ...
... Going out like a brilliant flame is one way ... a form of programmed suicide called apoptosis, a desired effect ... could more quickly pick the most effective treatment. Now scientists ... way to do just that, by lighting up cells as ...
... A new study by researchers from the Automotive Safety Program ... Medicine published online July 13, 2009 in the journal ... health care needs are doing a good job with the ... help in using it correctly. The study, one of ...
... to aid in understanding childhood brain development and healthy ... Deficit Hyperactivity Disorder and detecting the early onset of ... million in recent funding from the Canadian Institutes of ... makes us human is the ability to control our ...
... , , WASHINGTON, July 13 ... creation of a National Diabetes Coordinator to develop and implement a nationwide ... , , A study commissioned by NCDP ... The coordinator would be responsible for establishing priorities in the fight ...
... , , , WASHINGTON, ... in Congress, the Institute for America,s Future today released the names ... All the experts favor a public health insurance option to compete with ... to the health care debate. , , ...
Cached Medicine News:Health News:Avacor(R), Premier Provider of Hair Growth Solutions, Acquired By Investor Group. 2Health News:Fluorescent probes may permit monitoring of chemotherapy effectiveness, Stanford study shows 2Health News:Fluorescent probes may permit monitoring of chemotherapy effectiveness, Stanford study shows 3Health News: Making the difficult task of transporting a child with special needs safer 2Health News:Queen's University study aims at early diagnosis for ADHD and Parkinson's disease 2Health News:Diabetes Advocates Call For National Strategy, Leadership to Reduce Diabetes and Advance Detection and Treatment 2Health News:Diabetes Advocates Call For National Strategy, Leadership to Reduce Diabetes and Advance Detection and Treatment 3Health News:Diabetes Advocates Call For National Strategy, Leadership to Reduce Diabetes and Advance Detection and Treatment 4Health News:Prominent Health Experts Who Support Public Insurance Option Available for Interview 2Health News:Prominent Health Experts Who Support Public Insurance Option Available for Interview 3Health News:Prominent Health Experts Who Support Public Insurance Option Available for Interview 4Health News:Prominent Health Experts Who Support Public Insurance Option Available for Interview 5
(Date:7/11/2014)... /PRNewswire-iReach/ -- VAPETEK™, Inc. has announced a new ... in portable vaporizers, which contains CBD, or cannabodiol. ... cannabidiol offers consumers a THC-free product made for ... technology. Photo - http://photos.prnewswire.com/prnh/20140711/126344 ... compounds which are currently known, two of which ...
(Date:7/11/2014)... July 11, 2014 The consumer marketing ... across industry sectors to better identify winning tools ... to engage with and understand consumers, as new ... make critical purchasing decisions. According ... LLC, one area where organizations can observe a ...
(Date:7/11/2014)... 11, 2014 Research and Markets ... Chinese Medical X-ray Film Industry Report 2014" report ... Global And Chinese Medical X-Ray Film ... on the current state of the Global medical X-ray ... The report provides a basic overview of the ...
Breaking Medicine Technology:VAPETEK Releases CBD-Infused eLiquid For The Consumer Market 2New Technologies Transforming Consumer Marketing Research Playbook 2Global and Chinese Medical X-ray Film Industry Report 2014 2
... WELLESLEY, Mass., Oct. 26 Coley,Pharmaceutical Group, Inc. ... company,has received a $3.0 million milestone payment from ... III clinical trial in,non-small cell lung cancer (NSCLC) ... adjuvant. In June 2007, GSK announced the ...
... at AACR-NCI-EORTC ... Symposium, ... MTAX: CTIC) and Systems Medicine, LLC (SM), a,wholly-owned subsidiary of CTI, ... 19th annual AACR-NCI-EORTC Symposium. "These studies show potential progress toward ...
Cached Medicine Technology:Coley Pharmaceutical Group Receives $3.0 Million Milestone Payment from GlaxoSmithKline 2Coley Pharmaceutical Group Receives $3.0 Million Milestone Payment from GlaxoSmithKline 3Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development 2Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development 3Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development 4Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development 5
Inquire...
Integrated closure system provides security you can feel as the plastic fasteners lock into place and is both easy to close, empty and clean....
Flextend is a hydrocolloid skin barrier that is designed to be the most resistant to discharge and is the barrier of choice for urostomies and high output ileosotomies....
Inquire...
Medicine Products: